Epigenetic assay has a high negative predictive value for prostate cancer.
Study reveals a 2-fold greater likelihood of primary kidney and bladder cancer compared with men in the general population.
Patients with substance use disorder are more likely to be hospitalized and to make emergency department visits.
Experts note study findings aren't definitive, and risk is minimal.
Study finds a 19% increased risk of distant metastases or death from the cancer.
Those with depression, intermediate- or high-risk disease undergo less treatment.
Men who took cranberry capsules during and after external beam radiation treatment experienced less severe symptoms of cystitis.
Use of low-molecular-weight heparin decreased the risk of death by 52%.
In a study, the biochemical recurrence-free and metastasis-free survival rates were 73% and 97.5%, respectively, at 10 years.
Prostate cancer patients with health insurance are less likely to present with metastatic disease or die from the cancer than uninsured patients.
After 5 years, nearly two thirds of men remained on active surveillance.
Men aged 61 and older at diagnosis are more likely to die from the malignancy than men aged 50 or younger.
Transient rises in PSA after radiotherapy may be due to late damage to healthy prostatic tissue, evidence suggests.
Increased long-term risk observed in men on active surveillance.
Most physicians report that their patients are not interested in active surveillance.
Compared with whites, blacks and Hispanics have 42% and 23% increased odds, respectively, of being diagnosed with high-risk prostate cancer.
Other predictors include the presence of more than 1 positive biopsy core and a greater tumor burden.
This rate of incidental PCa detection is lower than found in previous studies.
Reasons for decline may include muscle pain, fatigue, and weakness caused by statins.
Other oral hypoglycemic agents have no effect on the risk.
Issues addressed include health promotion; surveillance for recurrence, new primaries.
A study suggests that a planned follow-up of at least 15 years after PCa treatment is reasonable.
Researchers report findings from a study of 942 hypogonadal men treated at 3 German centers.
Greatest protective effect observed in men circumcised at age 36 years or older.
The proportion of low-risk prostate cancer cases treated with this modality decreased by 14.3% from 2004 to 2010.
Starting docetaxel with androgen deprivation therapy prolonged median overall survival by more than 13 months versus ADT alone.
Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.
It also may lower the risk of positive surgical margins in men with non-palpable tumors.
Study of 1,146 radical prostatectomy patients reveals a 36% decreased risk of PSA relapse in those who used statins after surgery.
Study compared surgeons who performed fewer than 100 robot-assisted radical prostatectomies with those who performed 100 or more.